BMO Capital Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $24

BMO Capital analyst Do Kim upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $17 to $24.

Benzinga · 01/09/2020 14:09

BMO Capital analyst Do Kim upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $17 to $24.